Clinical pharmacokinetics of adavosertib in the presence or absence of PD-L1 inhibitor durvalumab in patients with refractory solid tumors. (October 2020) - Miah, M.K.; Imedio, E. R; Ottesen, L.; Kumar, S.; Mugundu, G.